SRR8613760
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8350-01A-11R-2296-07 | — | cohortSQ1 | 0.906 |
| 2 | SRR8613753 | — | C | 0.880 |
| 3 | MNG705 | — | — | 0.835 |
| 4 | BS_SD8YBRBR | high-grade glioma | — | 0.833 |
| 5 | a2a777ef-9294-4acf-b489-27bc17272b5e | — | — | 0.830 |
| 6 | TCGA-4H-AAAK-01A-12R-A41B-07 | — | A | 0.826 |
| 7 | BS_44A3ES23 | Med | Medulloblastoma | 0.824 |
| 8 | R7 | — | — | 0.815 |
| 9 | BS_YK6VQ9SJ | DNET | — | 0.813 |
| 10 | GSM6454752 | — | E | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |